joimax obtained full product registration from the Thai Food & Drug Administration. Certification in Japan, Malaysia and Taiwan is expected during 2017.
Results of evaluation of MicroPort Orthopedics’ Medial Pivot Knee demonstrated 95.0% satisfaction and 98.8% survivorship at 17 years, with patients reporting high stability and comfort during regular activity.
Independent study results indicate that mean wear associated with Amedica’s MC2® silicon nitride femoral heads was ~15% lower than a BIOLOX®delta sample after five million cycles.
Tissue Regenix plans a 2018 launch for dCELL® decellularization technology in the U.S. for orthopaedic applications, initially addressing ACL repair.Â